CN117355310A - 核糖醇治疗 - Google Patents

核糖醇治疗 Download PDF

Info

Publication number
CN117355310A
CN117355310A CN202180073484.0A CN202180073484A CN117355310A CN 117355310 A CN117355310 A CN 117355310A CN 202180073484 A CN202180073484 A CN 202180073484A CN 117355310 A CN117355310 A CN 117355310A
Authority
CN
China
Prior art keywords
day
ribitol
dose
comprises administering
method comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180073484.0A
Other languages
English (en)
Chinese (zh)
Inventor
陆其龙
吴波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charlotte Mecklenburg Hospital Authority D / B / A Acheson Health
Original Assignee
Charlotte Mecklenburg Hospital Authority D / B / A Acheson Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charlotte Mecklenburg Hospital Authority D / B / A Acheson Health filed Critical Charlotte Mecklenburg Hospital Authority D / B / A Acheson Health
Publication of CN117355310A publication Critical patent/CN117355310A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Molecular Biology (AREA)
CN202180073484.0A 2020-09-10 2021-09-09 核糖醇治疗 Pending CN117355310A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076761P 2020-09-10 2020-09-10
US63/076,761 2020-09-10
PCT/US2021/049677 WO2022056137A1 (en) 2020-09-10 2021-09-09 Ribitol treatment

Publications (1)

Publication Number Publication Date
CN117355310A true CN117355310A (zh) 2024-01-05

Family

ID=80629815

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180073484.0A Pending CN117355310A (zh) 2020-09-10 2021-09-09 核糖醇治疗

Country Status (10)

Country Link
US (1) US20230364118A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210708A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023544249A (cg-RX-API-DMAC7.html)
KR (1) KR20230069941A (cg-RX-API-DMAC7.html)
CN (1) CN117355310A (cg-RX-API-DMAC7.html)
AU (1) AU2021338706A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191582A1 (cg-RX-API-DMAC7.html)
IL (1) IL301088A (cg-RX-API-DMAC7.html)
MX (1) MX2023001881A (cg-RX-API-DMAC7.html)
WO (1) WO2022056137A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434113B2 (en) 2016-12-16 2019-10-08 The Charlotte Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
CN114269712A (zh) 2019-05-28 2022-04-01 夏洛特-梅克伦堡医院管理局D/B/A艾奇恩健康 制备核糖醇的组合物和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245235B2 (en) * 2016-12-16 2019-04-02 The Charlotte-Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
WO2020041750A1 (en) * 2018-08-24 2020-02-27 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Methods and compositions for treating disorders associated with muscle weakness

Also Published As

Publication number Publication date
AU2021338706A1 (en) 2023-05-25
WO2022056137A1 (en) 2022-03-17
US20230364118A1 (en) 2023-11-16
EP4210708A4 (en) 2024-10-23
WO2022056137A9 (en) 2022-04-14
JP2023544249A (ja) 2023-10-23
KR20230069941A (ko) 2023-05-19
CA3191582A1 (en) 2022-03-17
MX2023001881A (es) 2023-04-03
IL301088A (en) 2023-05-01
EP4210708A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
US12427161B2 (en) Methods for treating and pharmaceutical compositions
JP6387010B2 (ja) 血中グルコースレベルを制御することによる糖尿病及び関連容態の処置のための組成物、方法及び使用
JP6381521B2 (ja) ポンペ病の処置のための投与計画
CZ295567B6 (cs) Tetrahydrolipstatin pro výrobu orálního farmaceutického prostředku pro ošetřování typu II diabetes mellitus
TW201605434A (zh) 使用半胱胺及其衍生物治療粒腺體疾病
WO2002028348A2 (en) Compositions and methods for treatment of cystic fibrosis
TW200808324A (en) Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload
TW201713324A (zh) Ado抗性半胱胺類似物及其用途
US20230364118A1 (en) Ribitol treatment
US20200061092A1 (en) Methods and compositions for treating disorders associated with muscle weakness
US20260076986A1 (en) A combination of scyllo-inositol and flavones
CN101677972A (zh) 一种用于治疗神经变性疾病的奈拉美生的新组合物
US20180333399A1 (en) Method of improving liver function
WO2025212841A1 (en) Compositions and methods for treating diseases and disorders associated with muscle weakness
CN114053281B (zh) 治疗慢性肾病的方法和药物组合物
WO2026013261A1 (en) Nizubaglustat for use in the treatment of lysosomal storage disorders
HK40058710A (en) Dosing regimens for the treatment of pompe disease
HK40112795A (en) Dosing regimens for the treatment of pompe disease
HK40058710B (en) Dosing regimens for the treatment of pompe disease
AU2014346703A1 (en) Use of cysteamine and derivatives thereof to treat mitochondrial diseases
WO2012154778A1 (en) Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder
MX2012014757A (es) Composicion farmaceutica de una meglitinida y una tiazolidinediona o sus sales farmaceuticamente aceptables y su uso.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination